At the outset of the pandemic, biotechnology company Novavax was one of the frontrunners to bring a vaccine against COVID-19 to market. But nearly two years later, Novavax’s vaccine has yet to appear. In a compelling article, the BMJ details the repeated delays and setbacks that have torpedoed Novavax’s once-promising vaccine candidate and rendered it unnecessary now that other vaccines from Pfizer, Moderna, and AstraZeneca flood the global marketplace.